Peptide Research
Retatrutide Canada: Research Guide to Mechanism, Clinical Trials and Regulatory Status
Retatrutide (development code LY3437943) is an investigational once-weekly medicine developed by Eli Lilly that activates three meta...
BPC-157 Recovery Claims: What Human Evidence Actually Exists?
Human evidence for BPC-157 recovery claims remains very limited. Published human reports are small — knee pain, interstitial cystiti...
Peptides in Canada: Understanding Health Canada Authorization, Clinical Research and Regulatory Status
Understanding peptides in canada requires separating scientific research from Health Canada authorization. Some peptide-based medici...
Retatrutide Phase 3 Results: What the TRIUMPH-2 Trial Means for Canada
Explore the latest retatrutide Phase 3 results from TRIUMPH-2, weight-loss and A1C findings, Canadian clinical trials, and whether retatrutide is approved in Canada.
Retatrutide Phase 3 Results 2026: What Canadians Should Know
New TRIUMPH-2 Phase 3 data show substantial weight loss and A1C reductions with retatrutide. Here is what Canadians should know about the results, current trials, and regulatory status.